Latest News on Spravato, 2026

Spravato is the brand name for esketamine, a prescription nasal spray derived from ketamine
and approved by the FDA to treat severe forms of depression. We are happy to be able to offer
it at Rochester Holistic Psychiatry. Esketamine is a more potent, regulated form of the ketamine
molecule designed for intranasal absorption.

Unlike standard antidepressants that target serotonin or dopamine and take weeks to work,
Spravato targets the brain’s glutamate system. This different pathway can lead to symptom
relief within hours or days.

It is self-administered under medical supervision at a certified treatment center (REMS-certified
setting) where patients are monitored for at least two hours for side effects like dissociation or
blood pressure changes. It is never dispensed for home use.

Psychiatrists prescribe Spravato for adults with TRD, which means that their depression has not
improved after trying at least two different oral antidepressant medications. It is also used
alongside an oral antidepressant to rapidly reduce depressive symptoms in patients
experiencing major depressive disorder with acute suicidal thoughts or behavior.
Because traditional pills take 4 to 6 weeks to take effect, psychiatrists utilize Spravato when
patients need a faster intervention to shift severe, long-standing mood symptoms.

Johnson & Johnson’s Spravato continues to see major commercial growth and expanding real-
world study data as a method to help patients with treatment resistant depression.

Sales surged past $1 billion in the first half of 2026, building on roughly $1.7 billion in revenue
last year. Certified administration sites across the U.S. have expanded dramatically from 2,800
to over 7,000 locations to meet growing demand. Industry analysts note that Spravato’s
commercial rollout has successfully paved the market and logistical pathway for upcoming
psychiatric and psychedelic-derived drug launches.

Recent real-world data from an extensive study of 570 TRD patients demonstrated robust
effectiveness with sustained symptom stability and no relapse over a 6-month post-treatment
follow-up. Johnson & Johnson recently highlighted pooled remission data across six clinical
trials at major psychiatric forums, emphasizing rapid neural connectivity improvements via the
glutamate system.

Because Spravato requires strict 2-hour in-clinic monitoring, individual clinic capabilities can
fluctuate. Recent local disruptions (such as certified staff departures at select regional facilities)
underline how heavily patient access depends on specific on-site certified personnel.

For questions on Spravato and  appointments with us, write to us on our website or call (585) 442-
6960.